BACKGROUND: Patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) respond to ALK inhibitors. Clinically, the presence of ≥15% cells with rearrangements identified on break-apart fluorescence in situ hybridization (FISH) classifies tumors as positive. Increases in native and rearranged ALK copy number also occur. METHODS: In total, 1426 NSCLC clinical specimens (174 ALK-positive specimens and 1252 ALK-negative specimens) and 24 ALK-negative NSCLC cell lines were investigated. ALK copy number and genomic status were assessed by FISH. RESULTS: Clinical specimens with 0% to 9%, 10% to 15%, 16% to 30%, 31% to 50%, and >50% ALK-positive cells were identified in 79.3%, 8.5%, 1.4%, 2.7%, and 8.1%, respectively. An increased native ALK copy number (≥3 copies per cell in ≥40% of cells) was detected in 19% of ALK-positive tumors and in 62% of ALK-negative tumors. In ALK-negative tumors, abundant, focal amplification of native ALK was rare (0.8%). Other atypical patterns occurred in approximately 6% of tumors. The mean native ALK copy number ranged from 2.1 to 6.9 copies in cell lines and was not correlated with crizotinib sensitivity (50% inhibitory concentration, 0.34-2.8 μM; r = 0.279; P = .1764). Neither native or rearranged ALK copy number nor the percentage of positive cells correlated with extra-central nervous system progression-free survival in ALK-positive patients who were receiving crizotinib. CONCLUSIONS: Overall, 8.5% of tumors fell below the established positivity threshold by ≤5%. Further investigation of ALK by other diagnostic techniques in such cases may be warranted. Native ALK copy number increases alone were not associated with sensitivity to ALK inhibition in vitro. However, rare, complex patterns of increased native ALK in patients should be studied further; because, otherwise, atypical rearrangements contained within these may be missed.
BACKGROUND:Patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) respond to ALK inhibitors. Clinically, the presence of ≥15% cells with rearrangements identified on break-apart fluorescence in situ hybridization (FISH) classifies tumors as positive. Increases in native and rearranged ALK copy number also occur. METHODS: In total, 1426 NSCLC clinical specimens (174 ALK-positive specimens and 1252 ALK-negative specimens) and 24 ALK-negative NSCLC cell lines were investigated. ALK copy number and genomic status were assessed by FISH. RESULTS: Clinical specimens with 0% to 9%, 10% to 15%, 16% to 30%, 31% to 50%, and >50% ALK-positive cells were identified in 79.3%, 8.5%, 1.4%, 2.7%, and 8.1%, respectively. An increased native ALK copy number (≥3 copies per cell in ≥40% of cells) was detected in 19% of ALK-positive tumors and in 62% of ALK-negative tumors. In ALK-negative tumors, abundant, focal amplification of native ALK was rare (0.8%). Other atypical patterns occurred in approximately 6% of tumors. The mean native ALK copy number ranged from 2.1 to 6.9 copies in cell lines and was not correlated with crizotinib sensitivity (50% inhibitory concentration, 0.34-2.8 μM; r = 0.279; P = .1764). Neither native or rearranged ALK copy number nor the percentage of positive cells correlated with extra-central nervous system progression-free survival in ALK-positive patients who were receiving crizotinib. CONCLUSIONS: Overall, 8.5% of tumors fell below the established positivity threshold by ≤5%. Further investigation of ALK by other diagnostic techniques in such cases may be warranted. Native ALK copy number increases alone were not associated with sensitivity to ALK inhibition in vitro. However, rare, complex patterns of increased native ALK in patients should be studied further; because, otherwise, atypical rearrangements contained within these may be missed.
Authors: Ryohei Katayama; Alice T Shaw; Tahsin M Khan; Mari Mino-Kenudson; Benjamin J Solomon; Balazs Halmos; Nicholas A Jessop; John C Wain; Alan Tien Yeo; Cyril Benes; Lisa Drew; Jamal Carlos Saeh; Katherine Crosby; Lecia V Sequist; A John Iafrate; Jeffrey A Engelman Journal: Sci Transl Med Date: 2012-01-25 Impact factor: 17.956
Authors: Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge Journal: Clin Cancer Res Date: 2012-01-10 Impact factor: 12.531
Authors: Marta Salido; Lara Pijuan; Luz Martínez-Avilés; Ana B Galván; Israel Cañadas; Ana Rovira; Montserrat Zanui; Alejandro Martínez; Raquel Longarón; Francisco Sole; Sergio Serrano; Beatriz Bellosillo; Murry W Wynes; Joan Albanell; Fred R Hirsch; Edurne Arriola Journal: J Thorac Oncol Date: 2011-01 Impact factor: 15.609
Authors: D Ross Camidge; Scott A Kono; Antonella Flacco; Aik-Choon Tan; Robert C Doebele; Qing Zhou; Lucio Crino; Wilbur A Franklin; Marileila Varella-Garcia Journal: Clin Cancer Res Date: 2010-11-09 Impact factor: 12.531
Authors: Doron Lipson; Marzia Capelletti; Roman Yelensky; Geoff Otto; Alex Parker; Mirna Jarosz; John A Curran; Sohail Balasubramanian; Troy Bloom; Kristina W Brennan; Amy Donahue; Sean R Downing; Garrett M Frampton; Lazaro Garcia; Frank Juhn; Kathy C Mitchell; Emily White; Jared White; Zac Zwirko; Tamar Peretz; Hovav Nechushtan; Lior Soussan-Gutman; Jhingook Kim; Hidefumi Sasaki; Hyeong Ryul Kim; Seung-il Park; Dalia Ercan; Christine E Sheehan; Jeffrey S Ross; Maureen T Cronin; Pasi A Jänne; Philip J Stephens Journal: Nat Med Date: 2012-02-12 Impact factor: 53.440
Authors: Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris Journal: Expert Rev Anticancer Ther Date: 2009-03 Impact factor: 4.512
Authors: Andrew J Weickhardt; Dara L Aisner; Wilbur A Franklin; Marileila Varella-Garcia; Robert C Doebele; D Ross Camidge Journal: Cancer Date: 2012-12-20 Impact factor: 6.860
Authors: E Felip; Á Concha; J de Castro; J Gómez-Román; P Garrido; J Ramírez; D Isla; J Sanz; L Paz-Ares; F López-Ríos Journal: Clin Transl Oncol Date: 2014-10-29 Impact factor: 3.405
Authors: Francesco Facchinetti; Marcello Tiseo; Massimo Di Maio; Paolo Graziano; Emilio Bria; Giulio Rossi; Silvia Novello Journal: Transl Lung Cancer Res Date: 2016-06
Authors: Andrew J Weickhardt; Dara L Aisner; Wilbur A Franklin; Marileila Varella-Garcia; Robert C Doebele; D Ross Camidge Journal: Cancer Date: 2012-12-20 Impact factor: 6.860
Authors: Esther Conde; Ana Suárez-Gauthier; Amparo Benito; Pilar Garrido; Rosario García-Campelo; Michele Biscuola; Luis Paz-Ares; David Hardisson; Javier de Castro; M Carmen Camacho; Delvys Rodriguez-Abreu; Ihab Abdulkader; Josep Ramirez; Noemí Reguart; Marta Salido; Lara Pijuán; Edurne Arriola; Julián Sanz; Victoria Folgueras; Noemí Villanueva; Javier Gómez-Román; Manuel Hidalgo; Fernando López-Ríos Journal: PLoS One Date: 2014-09-23 Impact factor: 3.240
Authors: Petra Martin; Carolyn J Shiau; Maria Pasic; Ming Tsao; Suzanne Kamel-Reid; Stephanie Lin; Roxana Tudor; Susanna Cheng; Brian Higgins; Ronald Burkes; Matilda Ng; Saroosh Arif; Peter M Ellis; Stacy Hubay; Sara Kuruvilla; Scott A Laurie; Jing Li; David Hwang; Anthea Lau; Frances A Shepherd; Lisa W Le; Natasha B Leighl Journal: Br J Cancer Date: 2016-02-18 Impact factor: 7.640
Authors: Manfred Dietel; Lukas Bubendorf; Anne-Marie C Dingemans; Christophe Dooms; Göran Elmberger; Rosa Calero García; Keith M Kerr; Eric Lim; Fernando López-Ríos; Erik Thunnissen; Paul E Van Schil; Maximilian von Laffert Journal: Thorax Date: 2015-11-03 Impact factor: 9.139
Authors: U Peretti; R Ferrara; S Pilotto; S Kinspergher; M Caccese; A Santo; M Brunelli; A Caliò; L Carbognin; I Sperduti; M Garassino; M Chilosi; A Scarpa; G Tortora; E Bria Journal: Respir Res Date: 2016-08-25